Lev Gertsik - Concepedia

Author

Lev Gertsik

Los Angeles Clinical Trials

Also Known As

L G Gertsik, L. Gertsik, Lev Gertsik

Publications

621

Citations

H-Index

Concepts

All Affiliations

Los Angeles Clinical Trials Cedars-Sinai Medical Center PAREXEL International (United States)Harbor–UCLA Medical Center Meharry Medical College

About

Lev Gertsik is an author at Los Angeles Clinical Trials specializing in medicine, psychiatry, and psychopharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	169
2	Social Sciences	3	3	139
3	Neuroscience	2	2	123
4	Endocrinology	1	1	13
5	Neurology	1	1	39

Lev Gertsik

Publications

581

Citations

H-Index

Page 1

	Year	Citations
Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder Lev Gertsik, Russell E. Poland, Catherine Bresee, Journal of Clinical Psychopharmacology	2011	162
AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study Robert E. Litman, Mark A. Smith, James Doherty, Schizophrenia Research Molecular PharmacologyPsychiatryPsychotic DisorderMedicinePrinciple Study	2016	84
Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial Kari R. Nations, Peter Dogterom, Roberta Bursi, Journal of Psychopharmacology	2012	70
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients Maurizio Fava, Karl Johe, Larry Ereshefsky, Molecular Psychiatry	2015	40
Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response Geoffrey E. Ott, Uma Rao, Keh‐Ming Lin, The International Journal of Neuropsychopharmacology Sleep DisordersNeuropsychologyPsychotropic MedicationPsychopharmacologyPharmacotherapy	2004	39
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia Nicholas DeMartinis, Rene N. Lopez, Eve H. Pickering, Journal of Clinical Psychopharmacology	2019	33
Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients Kari R. Nations, Roberta Bursi, Peter Dogterom, Drugs in R&D	2012	22
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events Paul Goldsmith, John Affinito, Maggie McCue, Drugs in R&D	2017	19
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia Amit Desai, Lauren Benner, Ruishan Wu, Neuropsychopharmacology	2020	19
Open-Label, Randomized, Parallel-Group Controlled Clinical Trial of Massage for Treatment of Depression in HIV-Infected Subjects Russell E. Poland, Lev Gertsik, Joya T. Favreau, The Journal of Alternative and Complementary Medicine	2012	18

Page 1